Cargando…

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma

SIMPLE SUMMARY: Due to the complex mechanism of actions, immunomodulatory drugs (IMiDs) are one of the primary drug classes used to treat multiple myeloma (MM). IMiDs are the backbone of treatment for both newly diagnosed, post-transplant maintenance, and relapsed/refractory MM. The standard of care...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charliński, Grzegorz, Vesole, David H., Jurczyszyn, Artur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468542/ https://www.ncbi.nlm.nih.gov/pubmed/34572892 http://dx.doi.org/10.3390/cancers13184666

Ejemplares similares

State of Oral Mucosa as an Additional Symptom in the Course of Primary Amyloidosis and Multiple Myeloma Disease
por: Czerniuk, Maciej R., et al.
Publicado: (2014)

In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon
por: Murai, Takahiro, et al.
Publicado: (2016)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
por: Butrym, Aleksandra, et al.
Publicado: (2017)

Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation
por: Shi, Qinglin, et al.
Publicado: (2017)

Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma
por: Chang, Xiubao, et al.
Publicado: (2017)

Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs
por: Gemechu, Yohannes, et al.
Publicado: (2018)

The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling
por: Shen, Chen, et al.
Publicado: (2021)

Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
por: Costacurta, Matteo, et al.
Publicado: (2021)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
por: Girardini, Miriam, et al.
Publicado: (2019)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
por: Hideshima, Teru, et al.
Publicado: (2020)

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
por: Jones, J. R., et al.
Publicado: (2021)

PB1958: IN SILICO ANALYSIS OF SYNONYMOUS AND NON-SYNONYMOUS SNPS OF THE HUMAN CEREBLON (CRBN) GENE: AN IMPORTANT GENE IN IMMUNOMODULATORY DRUGS (IMIDS)-BASED TREATMENT OF MULTIPLE MYELOMA PATIENTS
por: Güler, M., et al.
Publicado: (2022)

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples
por: Ren, Yan, et al.
Publicado: (2016)

Effect of a 6-Week Cycle of Nordic Walking Training on Vitamin 25(OH)D(3,) Calcium-Phosphate Metabolism and Muscle Damage in Multiple Myeloma Patients–Randomized Controlled Trial
por: Czerwińska-Ledwig, Olga, et al.
Publicado: (2022)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia
por: Banaszkiewicz, Małgorzata, et al.
Publicado: (2019)

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
por: Patel, Urmeel H., et al.
Publicado: (2015)

Adherence to immunomodulatory drugs in patients with multiple myeloma
por: Cransac, Amélie, et al.
Publicado: (2019)

New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies
por: Woziwodzka, Karolina, et al.
Publicado: (2020)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma
por: Tachita, Takuto, et al.
Publicado: (2020)

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator
por: Ye, Ying, et al.
Publicado: (2020)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function
por: Zhou, Liang, et al.
Publicado: (2020)

Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator
por: Wu, Fan, et al.
Publicado: (2023)

Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival
por: Xu, Qinqin, et al.
Publicado: (2016)

Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
por: Wester, R., et al.
Publicado: (2023)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
por: Chen, Lucia Y., et al.
Publicado: (2022)

The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels
por: Chen, Yi-An, et al.
Publicado: (2015)

Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs
por: Bai, Nan, et al.
Publicado: (2022)

Chemical Ligand Space of Cereblon
por: Boichenko, Iuliia, et al.
Publicado: (2018)

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2014)

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
por: Hideshima, T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vpbeoeaob0cg1d7v7nu6859odu